Clinical Research Directory

Inclusion Criteria: * BMI 30-40 mg/kg2 for adults by international cut-off points (for diagnosis of obesity) * Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. * Stable body weight during the previous 90 days before screening (\<5 kg self-reported weight change) * History of failing to lose sufficient weight with lifestyle modification as judged by the investigator and documented in subject's medical record. Exclusion Criteria: * Type 1 or type 2 diabetes mellitus (T1DM) * Subjects with secondary causes of obesity (i.e., hypothalamic, genetic, or endocrine causes) * Treatment with medications within 90 days before screening that, that are used in obesity treatment including pramlintide, orlistat, zonisamide, topiramate, lorcaserin, phentermine, bupropion, naltrexone, glucagon-like peptide-1 (GLP-1) receptor agonists, or metformin (used as treatment for obesity) * On anti-diabetic treatment * Patients with impaired kidney function including persistent eGFR \<= 45 and albuminuria * Patients with peripheral vascular disease * Patients with recurrent urinary tract infection or fungal infections within 12 months before screening * History of major depressive disorder within 2 years before screening * History of cardiopulmonary diseases that prevents from physical activity * Pregnancy